Hi-Tech Pharmacal Co., Inc. HITK announced today that they acquired marketing and distribution rights to an ANDA filing from KVK-Tech, Inc. for dexbrompheniramine maleate 6mg/pseudoephedrine sulfate 120 mg extended release tablets. The product will be marketed by ECR, Hi-Tech's branded sales and marketing company under the Lodrane® brand name.
David Seltzer, Hi-Tech's President and CEO said, “We are pleased to have the near-term opportunity to introduce through ECR an extended release antihistamine/decongestant. The product is similar to our Lodrane® brand products and will allow us to leverage significant equity in the brand, particularly as approximately 500 unapproved cough/cold and allergy products will be removed from the market in September 2011.”
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in